Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 31.40

From 52W high−57.90%

Volume2.22M

Market capCNY 3.94B

P/E (TTM)93.6x

P/S (TTM)5.4x

Div yield0.32%

Key dataSep 18, 2026

Open

CNY 31.40

From 52W high

−57.90%

Volume

2.22M

Market cap

CNY 3.94B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

36.1x

P/E (TTM)

93.6x

RSI (14)

47.7

MomentumView details →

1D Return

−0.33%

YTD Return

−37.77%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

93.6x

EV/EBITDA

36.1x

EV/Sales

5.8x

P/S (TTM)

5.4x

P/B (TTM)

3.7x

ProfitabilityView details →

Gross Margin

80.82%

Net Margin

6.44%

EBITDA Margin

16.03%

ROE (TTM)

4.15%

ROA (TTM)

2.90%

Asset Turnover

0.45x

GrowthView details →

Revenue YoY

+26.97%

EPS YoY

+5.95%

FCF YoY

—

Revenue CAGR 3Y

+8.42%

EPS CAGR 3Y

+9.03%

EBITDA YoY

—

MomentumView details →

1D Return

−0.33%

YTD Return

−37.77%

1Y Return

−48.31%

RSI (14)

47.7

vs 50D SMA

−3.69%

vs 200D SMA

−23.52%

Capital & dividendView details →

Debt/Equity

0.24x

Current Ratio

1.07x

Quick Ratio

0.83x

Div Yield

0.32%

Div Rate

CNY 0.10

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

688.74M

Net Income (TTM)

44.38M

Op. CF (TTM)

45.54M

Latest newsMore news →

Haichen Pharmaceutical plans to acquire the minority shareholders' equity in its controlling subsidiary.2d ago

Haisheng Pharmaceutical announced it will acquire the remaining 25% stake in its controlling subsidiary Anqing Huichen for 64.5083 million yuan plus 0 yuan, raising its holding from 75% to 100% and making Anqing Huichen a wholly owned subsidiary.3d ago

Similar companies

银宝山新002786.SZ 申昊科技300853.SZ ST龙大002726.SZ 森远股份300210.SZ 大地海洋301068.SZ 宝莱特300246.SZ Find similar companies →

Latest newsMore news →

Haichen Pharmaceutical plans to acquire the minority shareholders' equity in its controlling subsidiary.2d ago Haisheng Pharmaceutical announced it will acquire the remaining 25% stake in its controlling subsidiary Anqing Huichen for 64.5083 million yuan plus 0 yuan, raising its holding from 75% to 100% and making Anqing Huichen a wholly owned subsidiary.3d ago Haishen Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 32.065 million yuan, up 9.97% year-on-year.27d ago